Amber Therapeutics strengthens its Board and Leadership team, opens UK headquarters and expands EU feasibility study for mixed urinary incontinence, increasing momentum towards a pivotal trial in the US

Oxford, UK – 24 February 2026  –   Amber Therapeutics today announced a series of updates to its business highlighting the significant progress it has made since closing its $100 million (£80 million) Series A financing in July 2024—one of the largest Series A rounds ever raised by a European medical technology company. New appointees to Board and Leadership team bring global strategic, operational and commercial experience from across the medical device sector.New headquarters and state-of-the-art manufact ...